Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters Hospitals in the Punjab province of Pakistan
et al., Exploratory Research in Clinical and Social Pharmacy, doi:10.1016/j.rcsop.2021.100101, Dec 2021
Retrospective 444 hospitalized patients in Pakistan, showing lower mortality with remdesivir treatment in unadjusted results, not reaching statistical significance.
Gérard, Zhou, Wu, Kamo, Choi, Kim show increased risk of acute kidney injury, Leo, Briciu, Muntean, Petrov show increased risk of liver injury, and Negru, Cheng, Mohammed show increased risk of cardiac disorders with remdesivir.
Remdesivir efficacy disappears with longer
followup. Mixed-effects meta-regression of efficacy as a function of
followup duration across all remdesivir studies shows decreasing efficacy with
longer followup14. This may reflect
antiviral efficacy being offset by serious adverse effects of treatment.
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
Study covers aspirin, remdesivir, and ivermectin.
|
risk of death, 32.7% lower, RR 0.67, p = 0.21, treatment 16 of 200 (8.0%), control 29 of 244 (11.9%), NNT 26.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
1.
Gérard et al., Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.2145.
2.
Zhou et al., Acute Kidney Injury and Drugs Prescribed for COVID-19 in Diabetes Patients: A Real-World Disproportionality Analysis, Frontiers in Pharmacology, doi:10.3389/fphar.2022.833679.
3.
Wu et al., Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS, Frontiers in Pharmacology, doi:10.3389/fphar.2022.692828.
4.
Kamo et al., Association of Antiviral Drugs for the Treatment of COVID-19 With Acute Renal Failure, In Vivo, doi:10.21873/invivo.13637.
5.
Choi et al., Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study, The Lancet Infectious Diseases, doi:10.1016/S1473-3099(24)00353-0.
6.
Kim et al., Investigating the Safety Profile of Fast‐Track COVID‐19 Drugs Using the FDA Adverse Event Reporting System Database: A Comparative Observational Study, Pharmacoepidemiology and Drug Safety, doi:10.1002/pds.70043.
7.
Leo et al., Hepatocellular liver injury in hospitalized patients affected by COVID-19: Presence of different risk factors at different time points, Digestive and Liver Disease, doi:10.1016/j.dld.2021.12.014.
8.
Briciu et al., Evolving Clinical Manifestations and Outcomes in COVID-19 Patients: A Comparative Analysis of SARS-CoV-2 Variant Waves in a Romanian Hospital Setting, Pathogens, doi:10.3390/pathogens12121453.
9.
Muntean et al., Effects of COVID-19 on the Liver and Mortality in Patients with SARS-CoV-2 Pneumonia Caused by Delta and Non-Delta Variants: An Analysis in a Single Centre, Pharmaceuticals, doi:10.3390/ph17010003.
10.
Petrov et al., The Effect of Potentially Hepatotoxic Medicinal Products on Alanine Transaminase Levels in COVID-19 Patients: A Case–Control Study, Safety and Risk of Pharmacotherapy, doi:10.30895/2312-7821-2025-458.
11.
Negru et al., Comparative Pharmacovigilance Analysis of Approved and Repurposed Antivirals for COVID-19: Insights from EudraVigilance Data, Biomedicines, doi:10.3390/biomedicines13061387.
12.
Cheng et al., Cardiovascular Safety of COVID-19 Treatments: A Disproportionality Analysis of Adverse Event Reports from the WHO VigiBase, Infectious Diseases and Therapy, doi:10.1007/s40121-025-01225-z.
Mustafa et al., 29 Dec 2021, retrospective, Pakistan, peer-reviewed, 7 authors.
Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters Hospitals in the Punjab province of Pakistan
Exploratory Research in Clinical and Social Pharmacy, doi:10.1016/j.rcsop.2021.100101
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
to 2.5 times the upper limit of normal
Declaration of interests ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: J o u r n a l P r e -p r o o f
References
Beigel, Tomashek, Dodd, Remdesivir for the Treatment of Covid-19 -Final Report, N Engl J Med
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res
Couderc, Jolivet, Thiébaut, Fluoroquinolone use is a risk factor for methicillinresistant Staphylococcus aureus acquisition in long-term care facilities: a nested case-casecontrol study, Clin Infect Dis
Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect Dis
Edalatifard, Akhtari, Salehi, Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial, Eur Respir J
Elgazzar, Hany, Youssef, Hafez, Moussa, Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic
Goligher, Bradbury, Mcverry, Therapeutic Anticoagulation in Critically Ill Patients with Covid-19-Preliminary Report, Preprint. medRxiv
Hajjar, Costa, Rizk, Intensive care management of patients with COVID-19: a practical approach, Ann Intensive Care
Horby, Lim, Dexamethasone in Hospitalized Patients with Covid-19, N Engl J Med
Kamel, Monem, Sharaf, Magdy, Farid, Efficacy and safety of azithromycin in Covid-19 patients: A systematic review and meta-analysis of randomized clinical trials
Kow, Aldeyab, Hasan, Effect of remdesivir on mortality in patients with COVID-19: A meta-analysis of randomized control trials, J Med Virol
Kow, Hasan, Concurrent Antibiotic Therapy in Disseminated Strongyloidiasis, Am J Trop Med Hyg
Kow, Hasan, Corticosteroid-related in-hospital hyperglycemia: does it negate mortality benefits in COVID-19?, Clin Infect Dis
Kow, Hasan, Could it be that the B.1.1.7 lineage is more deadly?
Kow, Hasan, Use of low-molecular-weight heparin in COVID-19 patients, J Vasc Surg Venous Lymphat Disord
Kow, Hasan, Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis, J Intern Med
Kow, Merchant, Hasan, Mortality risk in patients infected with SARS-CoV-2 of the lineage B.1.1.7 in the UK [published online ahead of print, J Infect
Kow, Merchant, Mustafa, Hasan, The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis
Langford, So, Raybardhan, Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis, Clin Microbiol Infect
Lawler, Goligher, Berger, Therapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19, Preprint. medRxiv
Liu, Chen, Liu, Nie, Lu, Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis, Aging Dis
Lopes, Silva, Furtado, Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial, Lancet
Mustafa, Aldeyab, Kow, Hasan, Antimicrobial consumption among hospitalized patients with COVID-19 in Pakistan
Niaee, Gheibi, Namdar, Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial, doi:10.21203/rs.3.rs-109670/v1
Pan, Peto, Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results, N Engl J Med
Ramakrishnan, Nicolau, Jr, Langford, Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial [published online ahead of print, Lancet Respir Med
Sieswerda, De Boer, Bonten, Recommendations for antibacterial therapy in adults with COVID-19 -an evidence based guideline, Clin Microbiol Infect
Singh, Parida, Lingaraju, Kesavan, Kumar et al., Drug repurposing approach to fight COVID-19, Pharmacol Rep
Tomazini, Maia, Cavalcanti, Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial, JAMA
Urbánek, Kolár, Lovecková, Strojil, Santavá, Influence of third-generation cephalosporin utilization on the occurrence of ESBL-positive Klebsiella pneumoniae strains, J Clin Pharm Ther
Yu, Bafadhel, Dorward, Hayward, Saville et al., Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial, Preprint. medrxiv
DOI record:
{
"DOI": "10.1016/j.rcsop.2021.100101",
"ISSN": [
"2667-2766"
],
"URL": "http://dx.doi.org/10.1016/j.rcsop.2021.100101",
"alternative-id": [
"S2667276621001013"
],
"article-number": "100101",
"author": [
{
"affiliation": [],
"family": "Mustafa",
"given": "Zia Ul",
"sequence": "first"
},
{
"affiliation": [],
"family": "Kow",
"given": "Chia Siang",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Salman",
"given": "Muhammad",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Kanwal",
"given": "Mahpara",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Riaz",
"given": "Muhammad Bilal",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Parveen",
"given": "Samina",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Hasan",
"given": "Syed Shahzad",
"sequence": "additional"
}
],
"container-title": [
"Exploratory Research in Clinical and Social Pharmacy"
],
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2021,
12,
29
]
],
"date-time": "2021-12-29T17:33:53Z",
"timestamp": 1640799233000
},
"deposited": {
"date-parts": [
[
2021,
12,
29
]
],
"date-time": "2021-12-29T17:34:09Z",
"timestamp": 1640799249000
},
"indexed": {
"date-parts": [
[
2021,
12,
29
]
],
"date-time": "2021-12-29T18:13:54Z",
"timestamp": 1640801634140
},
"is-referenced-by-count": 0,
"issn-type": [
{
"type": "print",
"value": "2667-2766"
}
],
"issued": {
"date-parts": [
[
2021,
12
]
]
},
"language": "en",
"license": [
{
"URL": "https://www.elsevier.com/tdm/userlicense/1.0/",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2021,
12,
1
]
],
"date-time": "2021-12-01T00:00:00Z",
"timestamp": 1638316800000
}
},
{
"URL": "http://creativecommons.org/licenses/by/4.0/",
"content-version": "vor",
"delay-in-days": 26,
"start": {
"date-parts": [
[
2021,
12,
27
]
],
"date-time": "2021-12-27T00:00:00Z",
"timestamp": 1640563200000
}
}
],
"link": [
{
"URL": "https://api.elsevier.com/content/article/PII:S2667276621001013?httpAccept=text/xml",
"content-type": "text/xml",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://api.elsevier.com/content/article/PII:S2667276621001013?httpAccept=text/plain",
"content-type": "text/plain",
"content-version": "vor",
"intended-application": "text-mining"
}
],
"member": "78",
"original-title": [],
"page": "100101",
"prefix": "10.1016",
"published": {
"date-parts": [
[
2021,
12
]
]
},
"published-print": {
"date-parts": [
[
2021,
12
]
]
},
"publisher": "Elsevier BV",
"reference": [
{
"DOI": "10.1016/S1473-3099(20)30120-1",
"article-title": "An interactive web-based dashboard to track COVID-19 in real time",
"author": "Dong",
"doi-asserted-by": "crossref",
"journal-title": "Lancet Infect Dis",
"key": "10.1016/j.rcsop.2021.100101_bb0005",
"year": "2020"
},
{
"article-title": "Could it be that the B.1.1.7 lineage is more deadly? [published online ahead of print, 2021 Feb 9]",
"author": "Kow",
"journal-title": "Infect Control Hosp Epidemiol",
"key": "10.1016/j.rcsop.2021.100101_bb0010",
"volume": "1",
"year": "2021"
},
{
"article-title": "Mortality risk in patients infected with SARS-CoV-2 of the lineage B.1.1.7 in the UK [published online ahead of print, 2021 may 13]",
"author": "Kow",
"first-page": "e14",
"issue": "1",
"journal-title": "J Inf Secur",
"key": "10.1016/j.rcsop.2021.100101_bb0015",
"volume": "83",
"year": "2021"
},
{
"DOI": "10.14336/AD.2020.0502",
"article-title": "Comorbid chronic diseases are strongly correlated with disease severity among COVID-19 patients: a systematic review and Meta-analysis",
"author": "Liu",
"doi-asserted-by": "crossref",
"first-page": "668",
"issue": "3",
"journal-title": "Aging Dis",
"key": "10.1016/j.rcsop.2021.100101_bb0020",
"volume": "11",
"year": "2020"
},
{
"DOI": "10.1186/s13613-021-00820-w",
"article-title": "Intensive care management of patients with COVID-19: a practical approach",
"author": "Hajjar",
"doi-asserted-by": "crossref",
"first-page": "36",
"issue": "1",
"journal-title": "Ann Intensive Care",
"key": "10.1016/j.rcsop.2021.100101_bb0025",
"volume": "11",
"year": "2021"
},
{
"DOI": "10.1007/s43440-020-00155-6",
"article-title": "Drug repurposing approach to fight COVID-19",
"author": "Singh",
"doi-asserted-by": "crossref",
"first-page": "1479",
"issue": "6",
"journal-title": "Pharmacol Rep",
"key": "10.1016/j.rcsop.2021.100101_bb0030",
"volume": "72",
"year": "2020"
},
{
"author": "Ministry of National Health Services, Regulations & Coordination, Government of Pakistan",
"key": "10.1016/j.rcsop.2021.100101_bb0035"
},
{
"DOI": "10.1056/NEJMoa2021436",
"article-title": "Dexamethasone in hospitalized patients with Covid-19",
"author": "Horby",
"doi-asserted-by": "crossref",
"first-page": "693",
"issue": "8",
"journal-title": "N Engl J Med",
"key": "10.1016/j.rcsop.2021.100101_bb0040",
"volume": "384",
"year": "2021"
},
{
"article-title": "Corticosteroid-related in-hospital hyperglycemia: does it negate mortality benefits in COVID-19? [published online ahead of print, 2020 Sep 18]",
"author": "Kow",
"journal-title": "Clin Infect Dis.",
"key": "10.1016/j.rcsop.2021.100101_bb0045",
"year": "2020"
},
{
"DOI": "10.4269/ajtmh.20-1059a",
"article-title": "Concurrent antibiotic therapy in disseminated strongyloidiasis",
"author": "Kow",
"doi-asserted-by": "crossref",
"first-page": "2149",
"issue": "5",
"journal-title": "Am J Trop Med Hyg",
"key": "10.1016/j.rcsop.2021.100101_bb0050",
"volume": "103",
"year": "2020"
},
{
"article-title": "Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial",
"author": "Yu",
"journal-title": "Preprint medrxiv",
"key": "10.1016/j.rcsop.2021.100101_bb0055",
"year": "2021"
},
{
"article-title": "Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial [published online ahead of print, 2021 Apr 9] [published correction appears in Lancet Respir Med. 2021 Jun;9(6):e55]",
"author": "Ramakrishnan",
"journal-title": "Lancet Respir Med.",
"key": "10.1016/j.rcsop.2021.100101_bb0060",
"year": "2021"
},
{
"DOI": "10.1016/j.antiviral.2020.104787",
"article-title": "The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro",
"author": "Caly",
"doi-asserted-by": "crossref",
"journal-title": "Antivir Res",
"key": "10.1016/j.rcsop.2021.100101_bb0065",
"volume": "178",
"year": "2020"
},
{
"article-title": "The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis [published online ahead of print, 2021 Mar 29]",
"author": "Kow",
"first-page": "1",
"journal-title": "Pharmacol Rep",
"key": "10.1016/j.rcsop.2021.100101_bb0070",
"year": "2021"
},
{
"article-title": "Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: a randomized multi-center clinical trial",
"author": "Niaee",
"journal-title": "Preprint Research Square",
"key": "10.1016/j.rcsop.2021.100101_bb0075",
"year": "2020"
},
{
"author": "Elgazzar",
"key": "10.1016/j.rcsop.2021.100101_bb0080",
"series-title": "Efficacy and safety of Ivermectin for treatment and prophylaxis of COVID-19 pandemic",
"year": "2020"
},
{
"DOI": "10.1002/jmv.26638",
"article-title": "Effect of remdesivir on mortality in patients with COVID-19: a meta-analysis of randomized control trials",
"author": "Kow",
"doi-asserted-by": "crossref",
"first-page": "1860",
"issue": "4",
"journal-title": "J Med Virol",
"key": "10.1016/j.rcsop.2021.100101_bb0085",
"volume": "93",
"year": "2021"
},
{
"DOI": "10.1056/NEJMoa2007764",
"article-title": "Remdesivir for the treatment of Covid-19 - final report",
"author": "Beigel",
"doi-asserted-by": "crossref",
"first-page": "1813",
"issue": "19",
"journal-title": "N Engl J Med",
"key": "10.1016/j.rcsop.2021.100101_bb0090",
"volume": "383",
"year": "2020"
},
{
"DOI": "10.1056/NEJMoa2023184",
"article-title": "Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results",
"author": "WHO Solidarity Trial Consortium",
"doi-asserted-by": "crossref",
"first-page": "497",
"issue": "6",
"journal-title": "N Engl J Med",
"key": "10.1016/j.rcsop.2021.100101_bb0095",
"volume": "384",
"year": "2021"
},
{
"DOI": "10.1016/j.cmi.2020.09.041",
"article-title": "Recommendations for antibacterial therapy in adults with COVID-19 - an evidence based guideline",
"author": "Sieswerda",
"doi-asserted-by": "crossref",
"first-page": "61",
"issue": "1",
"journal-title": "Clin Microbiol Infect",
"key": "10.1016/j.rcsop.2021.100101_bb0100",
"volume": "27",
"year": "2021"
},
{
"DOI": "10.1016/j.cmi.2020.12.018",
"article-title": "Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis",
"author": "Langford",
"doi-asserted-by": "crossref",
"first-page": "520",
"issue": "4",
"journal-title": "Clin Microbiol Infect",
"key": "10.1016/j.rcsop.2021.100101_bb0105",
"volume": "27",
"year": "2021"
},
{
"article-title": "Antimicrobial consumption among hospitalized patients with COVID-19 in Pakistan [published online ahead of print, 2021 May 28]",
"author": "Ul Mustafa",
"first-page": "1",
"journal-title": "SN Compr Clin Med",
"key": "10.1016/j.rcsop.2021.100101_bb0110",
"year": "2021"
},
{
"article-title": "Efficacy and safety of azithromycin in Covid-19 patients: a systematic review and meta-analysis of randomized clinical trials [published online ahead of print, 2021 Jun 2]",
"author": "Kamel",
"journal-title": "Rev Med Virol",
"key": "10.1016/j.rcsop.2021.100101_bb0115",
"year": "2021"
},
{
"DOI": "10.1093/cid/ciu236",
"article-title": "Fluoroquinolone use is a risk factor for methicillin-resistant Staphylococcus aureus acquisition in long-term care facilities: a nested case-case-control study",
"author": "Couderc",
"doi-asserted-by": "crossref",
"first-page": "206",
"issue": "2",
"journal-title": "Clin Infect Dis",
"key": "10.1016/j.rcsop.2021.100101_bb0120",
"volume": "59",
"year": "2014"
},
{
"DOI": "10.1111/j.1365-2710.2007.00836.x",
"article-title": "Influence of third-generation cephalosporin utilization on the occurrence of ESBL-positive Klebsiella pneumoniae strains",
"author": "Urbánek",
"doi-asserted-by": "crossref",
"first-page": "403",
"issue": "4",
"journal-title": "J Clin Pharm Ther",
"key": "10.1016/j.rcsop.2021.100101_bb0125",
"volume": "32",
"year": "2007"
},
{
"article-title": "Therapeutic anticoagulation in critically ill patients with Covid-19-preliminary report",
"author": "Goligher",
"journal-title": "Preprint medRxiv",
"key": "10.1016/j.rcsop.2021.100101_bb0130",
"year": "2021"
},
{
"article-title": "Therapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19",
"author": "Lawler",
"journal-title": "Preprint. medRxiv",
"key": "10.1016/j.rcsop.2021.100101_bb0135",
"year": "2021"
},
{
"article-title": "Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial",
"author": "Lopes",
"first-page": "01203",
"issue": "21",
"journal-title": "Lancet.",
"key": "10.1016/j.rcsop.2021.100101_bb0140",
"volume": "S0140-6736",
"year": "2021"
},
{
"DOI": "10.1016/j.jvsv.2020.06.006",
"article-title": "Use of low-molecular-weight heparin in COVID-19 patients",
"author": "Kow",
"doi-asserted-by": "crossref",
"first-page": "900",
"issue": "5",
"journal-title": "J Vasc Surg Venous Lymphat Disord",
"key": "10.1016/j.rcsop.2021.100101_bb0145",
"volume": "8",
"year": "2020"
},
{
"DOI": "10.1111/joim.13183",
"article-title": "Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis",
"author": "Kow",
"doi-asserted-by": "crossref",
"first-page": "125",
"issue": "1",
"journal-title": "J Intern Med",
"key": "10.1016/j.rcsop.2021.100101_bb0150",
"volume": "289",
"year": "2021"
},
{
"DOI": "10.1001/jama.2020.17021",
"article-title": "Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial",
"author": "Tomazini",
"doi-asserted-by": "crossref",
"first-page": "1307",
"issue": "13",
"journal-title": "JAMA",
"key": "10.1016/j.rcsop.2021.100101_bb0155",
"volume": "324",
"year": "2020"
},
{
"DOI": "10.1183/13993003.02808-2020",
"article-title": "Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial",
"author": "Edalatifard",
"doi-asserted-by": "crossref",
"first-page": "2002808",
"issue": "6",
"journal-title": "Eur Respir J",
"key": "10.1016/j.rcsop.2021.100101_bb0160",
"volume": "56",
"year": "2020"
}
],
"reference-count": 32,
"references-count": 32,
"relation": {},
"score": 1,
"short-container-title": [
"Exploratory Research in Clinical and Social Pharmacy"
],
"short-title": [],
"source": "Crossref",
"subtitle": [],
"title": [
"Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters Hospitals in the Punjab province of Pakistan"
],
"type": "journal-article"
}
Late treatment
is less effective
is less effective
mustafa